Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study

PaperCitations, authors & open-access status

Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 231 citations, 2022 year and hybrid oa status.

231
Citations
2022
Year
hybrid
OA Status

Related on ScholarIQ

Nicolas Girard
Author
Jair Bar
Author
Marina Chiara Garassino
Author
Benjamin Solomon
Author
Journal of Thoracic Oncology
Journal
Cancer Immunotherapy and Biomarkers
Topic
470M+ articles · free account